Table 1.

Description of Cases Associated With Microbiologic Failure Following Treatment With Meropenem-Vaborbactam

Age, y (Sex)	Underlying Disease	CRE Pathogen	Type of Initial Infection	Initial Treatment Regimen (Duration, d)	Clinical Outcome at 30 d	Time to Microbiologic Failure, da	Cause of Microbiologic Failure	MVB MIC Pre-Tx, µg/mL	MVB MIC Post-Tx, µg/mL
45 (F)	PUD w/ esophageal perforation s/p esophagectomy	KPC-3 Klebsiella pneumoniae	Primary bacteremia	MVB (19) plus IV gentamicin (1)	Failure	12	Abdominal wall abscessb	0.12	8c
76 (M)	Esophageal-pulmonary fistula s/p stent placement	KPC-3 K. pneumoniae	Primary bacteremia	MVB (14)	Success	49	Pneumonia	0.03	0.03
36 (M)	ESRD, CAD, s/p gastric sleeve procedure	KPC-3 K. pneumoniae	VAP	MVB (24) plus INH gentamicin (12)	Failure	41	Bacteremia	0.06	1
65 (M)	Disseminated peritoneal mucinous cancer	Escherichia coli	Peritonitis and abdominal abscess drained prior to Tx initiation	MVB (8)	Failure	67	Intra-abdominal abscess	0.03	0.5
83 (F)	ESRD, CRF	KPC-3 K. pneumoniae	Primary bacteremia	MVB (28)	Failure	10	Persistent bacteremia due to indwelling CVC	0.03	0.06
38 (F)	Respiratory failure due to influenza	KPC-3 K. pneumoniae	VAP	MVB (7) plus INH gentamicin (14)	Success	36	Respiratory colonization	0.03	0.03

Abbreviations: CAD, coronary artery disease; CRE, carbapenem-resistant Enterobacteriaceae; CRF, chronic respiratory failure; CVC, central venous catheter; ESRD, end-stage renal disease; F, female; INH, inhaled; IV, intravenous; KPC, Klebsiella pneumoniae carbapenemase; M, male; MIC, minimum inhibitory concentration; MVB, meropenem-vaborbactam; PUD, peptic ulcer disease; s/p, status-post; Tx, treatment; VAP, ventilator-associated pneumonia.

^aFrom the start of meropenem-vaborbactam treatment.

^bThe abscess was drained surgically and treatment was changed to intravenous ciprofloxacin, doxycycline, and metronidazole.

^cAssociated with an IS5 promoter insertion in ompK36 that was not present in the baseline isolate.